Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 5/2019

01-10-2019 | Tuberculosis | Review

Metformin in tuberculosis: beyond control of hyperglycemia

Authors: William Oglesby, Ali M. Kara, Hector Granados, Jorge L. Cervantes

Published in: Infection | Issue 5/2019

Login to get access

Abstract

Two global epidemics, diabetes mellitus (DM) and tuberculosis (TB), have converged making their control even more challenging. We herein have reviewed metformin’s (MTF) effect on patients with active and latent TB, as well as discussed its newly discovered biological mechanisms in mycobacteria. Mounting evidence suggests that MTF provides better outcomes in TB patients, especially those with DM. The mechanisms by which MTF produces its benefits are multiple. Though metformin’s potential has been proven in patients with DM, larger and more thorough clinical trials, in DM and non-DM-TB patients, need to be conducted. MTF could be added to the arsenal of anti-TB drugs, aiding in the goal of TB eradication worldwide.
Literature
1.
Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13:e1002152.CrossRef
2.
World Health Organization W. Global tuberculosis report. 2018. ISBN 978-92-4-156564-6
3.
Ruslami R, Aarnoutse RE, Alisjahbana B, van der Ven AJ, van Crevel R. Implications of the global increase of diabetes for tuberculosis control and patient care. Trop Med Int Health TM & IH. 2010;15:1289–99.CrossRef
4.
Jeon CY, Harries AD, Baker MA, Hart JE, Kapur A, Lonnroth K, et al. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop Med Int Health TM & IH. 2010;15:1300–14.CrossRef
5.
Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lonnroth K, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81.CrossRef
6.
Jeon CY, Murray M. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5(7):e152.CrossRef
7.
Chiang CY, Lee JJ, Chien ST, Enarson DA, Chang YC, Chen YT, et al. Glycemic control and radiographic manifestations of tuberculosis in diabetic patients. PLoS One. 2014;9:e93397.CrossRef
8.
Skowronski M, Zozulinska-Ziolkiewicz D, Barinow-Wojewodzki A. Tuberculosis and diabetes mellitus—an underappreciated association. Arch Med Sci AMS. 2014;10:1019–27.CrossRef
9.
Kang YA. Tuberculosis treatment in patients with comorbidities. Tuberc Respir Dis. 2014;76:257–60.CrossRef
10.
Leow MK, Dalan R, Chee CB, Earnest A, Chew DE, Tan AW, et al. Latent tuberculosis in patients with diabetes mellitus: prevalence, progression and public health implications. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Germ Diabetes Assoc. 2014;122(9):528–32.
11.
Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci. 2012;122:253–70.CrossRef
12.
El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275:223–8.CrossRef
13.
Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348:607–14.CrossRef
14.
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Investig. 2001;108:1167–74.CrossRef
15.
van Crevel R, Koesoemadinata R, Hill PC, Harries AD. Clinical management of combined tuberculosis and diabetes. Int J Tuberc Lung Dis Off J Int Union Against Tuberc Lung Dis. 2018;22:1404–10.CrossRef
16.
Lee MC, Chiang CY, Lee CH, Ho CM, Chang CH, Wang JY, et al. Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: a nationwide cohort study with validated diagnostic criteria. PLoS One. 2018;13:e0205807.CrossRef
17.
Tseng CH. Metformin decreases risk of tuberculosis infection in type 2 diabetes patients. J Clin Med. 2018;7(9):264.CrossRef
18.
Lin SY, Tu HP, Lu PL, Chen TC, Wang WH, Chong IW, et al. Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes. Respirology. 2018;23:1063–73.CrossRef
19.
Marupuru S, Senapati P, Pathadka S, Miraj SS, Unnikrishnan MK, Manu MK. Protective effect of metformin against tuberculosis infections in diabetic patients: an observational study of south Indian tertiary healthcare facility. Braz J Infect Dis Off Publ Braz Soc Infect Dis. 2017;21:312–6.
20.
Ma Y, Pang Y, Shu W, Liu YH, Ge QP, Du J, et al. Metformin reduces the relapse rate of tuberculosis patients with diabetes mellitus: experiences from 3-year follow-up. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2018;37:1259–63.CrossRef
21.
Novita BD, Soediono EI, Nugraha J. Metformin associated inflammation levels regulation in type 2 diabetes mellitus-tuberculosis coinfection patients—a case report. Indian J Tuberc. 2018;65:345–9.CrossRef
22.
Novita BD, Ali M, Pranoto A, Soediono EI, Mertaniasih NM. Metformin induced autophagy in diabetes mellitus–tuberculosis co-infection patients: a case study. Indian J Tuberc. 2019;66:64–9.CrossRef
23.
Lee YJ, Han SK, Park JH, Lee JK, Kim DK, Chung HS, et al. The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus. Korean J Intern Med. 2018;33:933–40.CrossRef
24.
Degner NR, Wang JY, Golub JE, Karakousis PC. Metformin use reverses the increased mortality associated with diabetes mellitus during tuberculosis treatment. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;66:198–205.CrossRef
25.
Cho SK, Yoon JS, Lee MG, Lee DH, Lim LA, Park K, et al. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther. 2011;89:416–21.CrossRef
26.
Te Brake LHM, Yunivita V, Livia R, Soetedjo N, van Ewijk-Beneken Kolmer E, Koenderink JB, et al. Rifampicin alters metformin plasma exposure but not blood glucose levels in diabetic tuberculosis patients. Clin Pharmacol Ther. 2018;105(3):730–7.CrossRef
27.
28.
Singhal A, Jie L, Kumar P, Hong GS, Leow MK, Paleja B, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med. 2014;6(263):263ra159.CrossRef
29.
Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife. 2014;3:e02242.CrossRef
30.
Vashisht R, Brahmachari SK. Metformin as a potential combination therapy with existing front-line antibiotics for tuberculosis. J Transl Med. 2015;13:83.CrossRef
31.
Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial persistence as a phenotypic switch. Science. 2004;305:1622–5.CrossRef
32.
Leung CC. Repurposing metformin to prevent and treat tuberculosis. Respirology. 2018;23:974–5.CrossRef
33.
Restrepo BI. Metformin: candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients. Tuberculosis. 2016;101S:S69–72.CrossRef
34.
Rayasam GV, Balganesh TS. Exploring the potential of adjunct therapy in tuberculosis. Trends Pharmacol Sci. 2015;36:506–13.CrossRef
35.
Carranza C, Chavez-Galan L. Several routes to the same destination: inhibition of phagosome-lysosome fusion by Mycobacterium tuberculosis. Am J Med Sci. 2019;357:184–94.CrossRef
36.
Koziel H, Koziel MJ. Pulmonary complications of diabetes mellitus. Pneumonia. Infect Dis Clin N Am. 1995;9:65–96.
37.
Guirado E, Schlesinger LS, Kaplan G. Macrophages in tuberculosis: friend or foe. Semin Immunopathol. 2013;35:563–83.CrossRef
38.
Kumari P, Meena LS. Factors affecting susceptibility to Mycobacterium tuberculosis: a close view of immunological defence mechanism. Appl Biochem Biotechnol. 2014;174:2663–73.CrossRef
39.
40.
Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature. 2010;466:973–7.CrossRef
41.
Lienard J, Movert E, Valfridsson C, Sturegard E, Carlsson F. ESX-1 exploits type I IFN-signalling to promote a regulatory macrophage phenotype refractory to IFNgamma-mediated autophagy and growth restriction of intracellular mycobacteria. Cell Microbiol. 2016;18:1471–85.CrossRef
42.
Teles RM, Graeber TG, Krutzik SR, Montoya D, Schenk M, Lee DJ, et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science. 2013;339:1448–53.CrossRef
43.
Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20:953–66.CrossRef
44.
Moller HJ, Aerts H, Gronbaek H, Peterslund NA, Hyltoft Petersen P, Hornung N, et al. Soluble CD163: a marker molecule for monocyte/macrophage activity in disease. Scand J Clin Lab Investig Suppl. 2002;237:29–33.CrossRef
45.
Su GL, Simmons RL, Wang SC. Lipopolysaccharide binding protein participation in cellular activation by LPS. Crit Rev Immunol. 1995;15:201–14.CrossRef
46.
Kumar NP, Moideen K, Bhootra Y, Nancy A, Viswanathan V, Shruthi BS, et al. Elevated circulating levels of monocyte activation markers among tuberculosis patients with diabetes co-morbidity. Immunology. 2018;156(3):249–58.PubMed
47.
Xu Y, Wang L, Zimmerman MD, Chen KY, Huang L, Fu DJ, et al. Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis. PLoS Pathog. 2018;14:e1006974.CrossRef
48.
Kumar NP, Moideen K, Viswanathan V, Shruthi BS, Sivakumar S, Menon PA, et al. Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment. BMC Infect Dis. 2018;18:345.CrossRef
Metadata
Title
Metformin in tuberculosis: beyond control of hyperglycemia
Authors
William Oglesby
Ali M. Kara
Hector Granados
Jorge L. Cervantes
Publication date
01-10-2019
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 5/2019
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-019-01322-5

Other articles of this Issue 5/2019

Infection 5/2019 Go to the issue

Case Report

Acute epididymo-orchitis due to Salmonella Typhi in a young man from Bangladesh

Original Paper

Species distribution and clinical features of infection and colonisation with non-tuberculous mycobacteria in a tertiary care centre, central Germany, 2006–2016

Original Paper

Influence of primary care antibiotic prescribing on incidence rates of multidrug-resistant Gram-negative bacteria in hospitalised patients

Case Report

A headache with surprising outcome: first case of brucellosis caused by Brucella suis biovar 1 in Germany

Original Paper

Early versus late onset bloodstream infection during neutropenia after high-dose chemotherapy for hematologic malignancy

Correspondence

Macrolides or fluoroquinolones as enteral antibiotic therapy for non-ICU legionellosis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits